CVR - Coronavirus Vaccines R&D Roadmap

Milestone
4.1.e

Standardization and validation

In progress
High priority

Make standardized and validated animal models available to evaluate and compare broadly protective coronavirus vaccines. Examples of parameters to consider include: viral challenge (strain, dose, route, volume, and timing), animal responses to human-adapted variants, and immune history. The appropriate surrogate markers of clinical disease severity, such as weight loss or virus titers in the lungs, are needed for each animal species and for each virus used to establish the model.

Progress Highlights

The CEPI Preclinical Model Network has established laboratory partners in Europe, the U.S., and Australia to develop and utilize animal models for coronavirus vaccine research. 

The Mutant Mouse Resource & Research Centers (MMRRCs), supported by the NIH’s Office of Research Infrastructure Programs (ORIP), was established to maintain and distribute mutant mouse strains. The MMRRCs ensure a reliable supply of new mouse strains, such as the humanized ACE2 knock-in mouse model, through a comprehensive strategy that combines centralized storage, active breeding, and quality control. The centers serve as a centralized repository, maintaining and distributing mutant mouse strains to the global research community via an online catalog. To safeguard long-term availability and address surges in demand, the MMRRCs rely on cryopreservation techniques, storing embryos and sperm to prevent the loss of genetic lines. Active breeding programs are carefully managed to maintain genetic integrity and ensure a steady supply of high-demand strains.